What are the presentation, staging, diagnostic work‑up, and management strategies for medullary thyroid carcinoma?

Medullary Thyroid Carcinoma: Comprehensive Overview

Introduction and Epidemiology

Medullary thyroid carcinoma (MTC) is a rare neuroendocrine malignancy arising from parafollicular C cells that accounts for 5–10% of all thyroid cancers, with approximately 75% occurring sporadically and 25% being hereditary, linked to germline RET proto-oncogene mutations in multiple endocrine neoplasia (MEN) 2A, MEN 2B, or familial MTC syndromes. 1

• MTC does not concentrate radioactive iodine and is relatively radioresistant, making surgery the only curative treatment modality. 1
• More than 50% of malignant thyroid nodules, including MTC, are asymptomatic at presentation. 2
• When symptomatic, patients may present with thyroid nodules (typically in the upper thyroid lobes), cervical lymphadenopathy, diarrhea, Cushing's syndrome, or facial flushing due to calcitonin and other hormone secretion. 2
• Physical examination findings that increase suspicion include very firm nodules, fixation to adjacent structures, rapid growth, enlarged regional lymph nodes, and vocal cord paralysis. 2

---

Genetic Basis and Hereditary Syndromes

All patients with newly diagnosed MTC—even those appearing to have sporadic disease—must undergo RET proto-oncogene DNA analysis, because approximately 6% of apparently sporadic cases harbor germline mutations, revealing previously unrecognized familial disease. 1

• RET mutations are identified in ≥95% of MEN 2A families and approximately 88% of familial MTC families. 1
• MEN 2A mutations occur primarily in codons of the cysteine-rich extracellular domains (exons 10,11,13), while MEN 2B mutations are found in intracellular exons 14–16, most commonly codon 918. 1
• Somatic RET mutations are found in at least 25% of sporadic MTC tumors, particularly the codon 918 mutation, which is associated with poorer prognosis. 1
• The codon 918 mutation is present in 91.4% of sporadic MTCs with distant metastases. 1
• Genetic counseling should be offered to all patients and their families. 1

---

Preoperative Investigation and Workup

Biochemical Markers

Measurement of basal serum calcitonin and carcinoembryonic antigen (CEA) is mandatory in all patients with suspected or confirmed MTC, as these markers are highly sensitive and specific for diagnosis, prognosis, and disease monitoring. 1

• Preoperative calcitonin levels correlate strongly with tumor diameter, nodal metastases, and postoperative outcomes. 1
• Calcitonin <20 pg/mL is associated with almost no risk of nodal metastases. 1
• Calcitonin >20 pg/mL indicates ipsilateral compartment nodal involvement; >50 pg/mL suggests contralateral central compartment nodes; >200 pg/mL indicates contralateral lateral compartment involvement; >500 pg/mL suggests distant metastatic disease. 1
• Patients with postoperative basal calcitonin <10 pg/mL are considered "biochemically cured" and have a 10-year survival rate of 97.7%. 1
• A rapidly increasing CEA level, particularly with stable calcitonin, predicts worse prognosis. 1

Imaging Studies

Preoperative neck ultrasound is recommended for all patients to evaluate the primary lesion and cervical lymph nodes, with suspicious features including central hypervascularity, microcalcifications, and irregular borders. 1, 2

• Contrast-enhanced CT of the chest and mediastinum or MRI should be obtained if the patient has N1 disease or calcitonin >400 pg/mL. 1
• For calcitonin >500 pg/mL, additional whole-body imaging is indicated to evaluate for distant metastases. 1
• Three-phase contrast-enhanced liver CT or MRI should be considered for comprehensive staging in advanced disease. 1, 2
• Vocal cord mobility evaluation is recommended preoperatively. 1

Screening for Associated Endocrinopathies

Before undertaking surgical therapy for MTC in patients with germline RET mutations, coexisting pheochromocytoma must be diagnosed and prospectively treated to avoid potentially fatal hypertensive crisis during surgery. 1

• Screen for pheochromocytoma using plasma metanephrines and normetanephrines or 24-hour urine collection for metanephrines in all MEN 2A and MEN 2B patients. 1, 2
• Pheochromocytoma can be removed through laparoscopic adrenalectomy prior to thyroidectomy. 1
• Measure serum calcium and intact parathyroid hormone to screen for hyperparathyroidism in MEN 2A patients. 1, 2
• Annual surveillance for pheochromocytoma and hyperparathyroidism is required lifelong in MEN 2A and MEN 2B patients. 2

Fine-Needle Aspiration

Fine-needle aspiration (FNA) is the preferred procedure for evaluating suspicious thyroid nodules, though the diagnosis of MTC requires demonstration of calcitonin expression on immunohistochemistry. 2, 3

• MTC is morphologically heterogeneous and can mimic virtually all other primary thyroid tumors. 1
• CEA determination can be useful in distinguishing MTC from metastatic neuroendocrine carcinomas, as MTC is the only neck tumor expressing this marker. 1

---

Staging

MTC staging follows the AJCC TNM classification system based on tumor size, extrathyroidal invasion, locoregional nodal metastases, and distant metastases, with the 7th edition (effective January 2010) downstaging T3,N0,M0 from stage III to stage II. 1

AJCC Staging Criteria

• Stage I: Tumor ≤2 cm without evidence of disease outside the thyroid gland. 1
• Stage II: Tumor >2 cm but ≤4 cm limited to the thyroid without nodal or distant metastases (7th edition includes T3,N0,M0). 1
• Stage III: Level 6 nodal metastases, minimal extrathyroidal invasion, or tumor >4 cm. 1
• Stage IV: Tumor extending beyond perithyroid soft tissues, lymph nodes beyond level 6, or distant metastatic sites. 1

Prognostic Factors

Age at diagnosis is a critical prognostic factor not captured by TNM staging: patients <40 years have 5- and 10-year disease-specific survival rates of approximately 95% and 75%, respectively, compared with 65% and 50% for those >40 years. 1

• In one study with median follow-up of 4 years, mortality from MTC was 0% for stage I, 13% for stage II, 56% for stage III, and 100% for stage IV disease. 1
• MEN 2B patients are more likely than MEN 2A or familial MTC patients to have locally aggressive disease despite younger age at diagnosis. 1
• Heterogeneity and paucity of calcitonin immunostaining predict worse prognosis. 1
• Postoperative residual hypercalcitoninemia indicates persistent disease. 1
• Exon 16 mutations (codon 918 in MEN 2B) are associated with more aggressive disease. 1

---

Surgical Management

Surgery is the primary and only curative treatment for MTC, with total thyroidectomy and compartment-oriented lymph node dissection offering the highest potential for cure, achieving biochemical cure (normocalcitoninemia) in more than 80% of cases. 1, 4, 5

Extent of Surgery

• Total thyroidectomy with central (level VI) and lateral neck dissection is the standard surgical approach. 4, 5
• Compartmental-oriented microdissection of cervical nodes has significantly improved primary surgery outcomes. 4
• For hereditary MTC, prophylactic total thyroidectomy timing is based on specific RET mutation risk stratification. 2

Prophylactic Thyroidectomy in RET Mutation Carriers

MEN 2B (codon 918,883): Total thyroidectomy should be performed within the first year of life, ideally before age 1, due to the most aggressive phenotype with earliest MTC onset. 2

MEN 2A high-risk (codon 634): Total thyroidectomy should be performed by age 5 years, or immediately if identified later. 2

MEN 2A lower-risk (codons 609,611,618,620,630,768,790,791,804,891): Total thyroidectomy by age 5 years is standard, though surgery may be delayed if annual basal calcitonin is normal, annual neck ultrasound is unremarkable, there is no aggressive family history, and the family consents. 2

Critical Preoperative Considerations

• Never proceed to thyroidectomy without first confirming the absence of pheochromocytoma in hereditary or RET-positive cases. 1, 2
• Obtain baseline calcitonin, CEA, and neck ultrasound before prophylactic surgery. 2
• Refer very young children to surgeons and multidisciplinary teams experienced in pediatric thyroid surgery. 2

---

Postoperative Management and Surveillance

Serum calcitonin should be measured 60–90 days after thyroidectomy, with patients achieving postoperative basal calcitonin <10 pg/mL considered biochemically cured and having a 10-year survival rate of 97.7%. 1

• After prophylactic or therapeutic thyroidectomy, measure serum calcitonin and CEA every 6–12 months to detect residual or recurrent disease. 2
• For calcitonin <150 pg/mL, perform cervical ultrasound every 6–12 months, as disease is nearly always confined to cervical lymph nodes. 6
• For calcitonin ≥150 pg/mL, perform contrast-enhanced CT of neck, chest, and abdomen, plus hepatic triphasic CT or MRI and bone scintigraphy. 6
• Maintain TSH in the normal range with levothyroxine replacement only; TSH suppression provides no benefit in MTC and increases risks of atrial fibrillation, osteoporosis, and cardiovascular complications. 6
• Check TSH levels every 6–12 months to ensure adequate replacement without over-suppression. 6

Persistent or Recurrent Disease

• Approximately 20% of patients will have recurrent or residual disease despite optimal primary surgery. 4
• Detailed investigation with ultrasound, cross-sectional imaging, nuclear imaging, and laparoscopy with liver biopsy may be required to select patients for further neck surgery. 4
• Reoperation may achieve normalization of calcitonin levels in about 40% of selected patients. 4

---

Systemic Therapy for Advanced Disease

For advanced, progressive, or metastatic MTC, selective RET inhibitors (selpercatinib, pralsetinib) offer precision treatment for RET-mutated tumors with high efficacy and fewer side effects compared to multikinase inhibitors (vandetanib, cabozantinib). 5

• Multikinase inhibitors extend progression-free survival but cause off-target effects. 5
• RET inhibitors show high response rates in RET-mutated MTC, though resistance has emerged. 5
• MTC does not respond to radioactive iodine therapy or conventional cytotoxic chemotherapy. 6, 4
• Do not rely solely on calcitonin levels during RET inhibitor therapy, as they may not correlate with actual tumor response. 6

---

Common Pitfalls and Caveats

• Never perform thyroidectomy before confirming and treating pheochromocytoma in hereditary cases; this can cause fatal hypertensive crisis. 1, 2
• Do not assume sporadic MTC without RET testing, as approximately 6% harbor germline mutations. 1
• Avoid TSH suppression therapy in MTC patients; it provides no benefit and causes harm. 6
• Do not delay comprehensive imaging when calcitonin exceeds 150 pg/mL or shows rapid doubling time. 6
• Inadequate screening for associated endocrinopathies in hereditary forms is a common diagnostic pitfall. 1
• Effective MTC management benefits from specialized high-volume centers given the rarity of the disease. 5